THE increasing enthusiasm for treating thromboembolic diseases with prothrombin-reducing drugs for long periods in ambulatory patients has emphasized the lack of clear definition of the therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results